Engineering IL-2 for immunotherapy of autoimmunity and cancer
R Hernandez, J Põder, KM LaPorte… - Nature Reviews …, 2022 - nature.com
Preclinical studies of the T cell growth factor activity of IL-2 resulted in this cytokine
becoming the first immunotherapy to be approved nearly 30 years ago by the US Food and …
becoming the first immunotherapy to be approved nearly 30 years ago by the US Food and …
CD8+ T Cell Exhaustion in Cancer
JS Dolina, N Van Braeckel-Budimir… - Frontiers in …, 2021 - frontiersin.org
A paradigm shift in the understanding of the exhausted CD8+ T cell (Tex) lineage is
underway. Originally thought to be a uniform population that progressively loses effector …
underway. Originally thought to be a uniform population that progressively loses effector …
Synthetic cytokine circuits that drive T cells into immune-excluded tumors
Chimeric antigen receptor (CAR) T cells are ineffective against solid tumors with
immunosuppressive microenvironments. To overcome suppression, we engineered circuits …
immunosuppressive microenvironments. To overcome suppression, we engineered circuits …
An engineered IL-2 partial agonist promotes CD8+ T cell stemness
Adoptive transfer of antigen-specific T cells represents a major advance in cancer
immunotherapy, with robust clinical outcomes in some patients. Both the number of …
immunotherapy, with robust clinical outcomes in some patients. Both the number of …
CD4+ T cell help in cancer immunology and immunotherapy
Cancer immunotherapy aims to promote the activity of cytotoxic T lymphocytes (CTLs) within
a tumour, assist the priming of tumour-specific CTLs in lymphoid organs and establish …
a tumour, assist the priming of tumour-specific CTLs in lymphoid organs and establish …
Signaling and function of interleukin-2 in T lymphocytes
SH Ross, DA Cantrell - Annual review of immunology, 2018 - annualreviews.org
The discovery of interleukin-2 (IL-2) changed the molecular understanding of how the
immune system is controlled. IL-2 is a pleiotropic cytokine, and dissecting the signaling …
immune system is controlled. IL-2 is a pleiotropic cytokine, and dissecting the signaling …
A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia
Q Zhang, ME Hresko, LK Picton, L Su… - Science translational …, 2021 - science.org
Interleukin-2 (IL-2) is a central T cell cytokine that promotes T cell proliferation and effector
function; however, toxicity due to its pluripotency limits its application to enhance CAR T cell …
function; however, toxicity due to its pluripotency limits its application to enhance CAR T cell …
Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer
Local environmental factors influence CD8+ T cell priming in lymph nodes (LNs). Here, we
sought to understand how factors unique to the tumor-draining mediastinal LN (mLN) impact …
sought to understand how factors unique to the tumor-draining mediastinal LN (mLN) impact …
Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer
In non–small cell lung cancer (NSCLC), response to immune checkpoint blockade (ICB) is
associated with programmed cell death ligand 1 expression that is induced by interferon-γ …
associated with programmed cell death ligand 1 expression that is induced by interferon-γ …
[HTML][HTML] Host immune response to influenza A virus infection
Influenza A viruses (IAVs) are contagious pathogens responsible for severe respiratory
infection in humans and animals worldwide. Upon detection of IAV infection, host immune …
infection in humans and animals worldwide. Upon detection of IAV infection, host immune …